This is a very rare type of cancer that starts in special cells called Langerhans cells. These cells are usually found in the skin and other parts of the body. The cancer cells look unusual under a microscope and tend to grow quickly. Doctors can tell it apart from other types of cancer by looking closely at the cells under a microscope and using special tests.
Every report comes from a Lived member, sent anonymously.
Have you had Chemotherapy infusion for Langerhans Cell Sarcoma?
Langerhans cell sarcoma is a rare and aggressive cancer of Langerhans cells, a type of immune cell normally found in the skin and lymph nodes. It most often shows up as a lump under the skin, an enlarged lymph node or a skin lesion, and it can also affect bone, the lungs, the bone marrow and other organs. Many people have disease in more than one place by the time it is found. The name is easy to confuse with Langerhans cell histiocytosis, a related condition involving the same cell type. The two are different diseases: in the sarcoma, the cells look clearly cancerous and divide rapidly, and the illness tends to grow and spread faster. Doctors group Langerhans cell sarcoma with a small family of cancers called malignant histiocytoses. It is so uncommon that most of what is known comes from individual case reports and small groups of patients.
The cause of Langerhans cell sarcoma is not known, and no lifestyle factor or exposure has been shown to bring it on. It is diagnosed mostly in adults, often in their 50s or 60s, although younger adults can be affected. The tumor cells usually carry acquired genetic changes, often in genes that control cell growth signals. These mutations develop in the tumor during life and are not inherited. In some people, the sarcoma appears alongside or after another blood cancer, such as a leukemia or lymphoma. This secondary form generally has a harder course than sarcoma that arises on its own.
Diagnosis requires a biopsy, in which a piece of the lump, lymph node or skin lesion is removed and examined by a pathologist. Special stains (immunohistochemistry) check for proteins that mark Langerhans cells, such as CD1a and langerin. Because Langerhans cell histiocytosis carries the same markers, the pathologist also looks for clearly abnormal cell features and a high Ki-67 index, a measure of how many cells are actively dividing. In this sarcoma the Ki-67 is typically very high, often above half of the cells. Review by a pathologist experienced in rare blood and immune cell tumors helps, since this cancer can be mistaken for other tumors. Once the diagnosis is made, imaging such as a CT (computed tomography) scan or PET (positron emission tomography) scan maps where the disease is in the body, and blood tests and sometimes a bone marrow biopsy check for involvement elsewhere or for another blood cancer. Genetic sequencing of the tumor is increasingly recommended, because some mutations can be treated with targeted medicines.
There is no standard treatment, because the disease is too rare for large trials. Care is usually guided by how far the disease has spread, and it is best planned at a center with experience in histiocytic cancers. When the cancer is limited to a single spot, surgery to remove it completely is the main approach and in published cases often leads to complete remission. Radiation may be added afterward or used for areas that cannot be removed. When the disease is in several places, chemotherapy is the usual starting point, using combinations borrowed from lymphoma or sarcoma treatment, and responses vary widely. If tumor sequencing finds a targetable change, targeted medicines may be an option, particularly if the cancer returns. These medicines block proteins called MEK and BRAF that relay growth signals inside the cell. They include trametinib (Mekinist), a MEK blocker, and, for tumors with a specific BRAF mutation known as V600E, dabrafenib (Tafinlar), a BRAF blocker. Both are oral cancer pills approved for other cancers and used off label here, with encouraging but limited evidence. For some people with widespread disease, a stem cell transplant is considered; it may offer longer control but involves intense treatment and is suitable only for those healthy enough to tolerate it. Clinical trials for rare histiocytic cancers are another option to ask about.
Langerhans cell sarcoma is a serious cancer, and its course varies a great deal from person to person. People whose disease is confined to one area and fully removed tend to do considerably better than those with disease in several organs, especially the bone marrow, spleen or liver. The outlook is also generally harder when the sarcoma occurs together with another blood cancer. Even after a good response, the cancer frequently comes back, so follow-up usually includes regular visits and repeat scans for years. Treatment may happen in phases, with a first therapy, a period of monitoring and a switch to a different approach if the disease returns. Because survival figures come from small and older groups of patients, they cannot predict any one person's course, and newer targeted treatments may be changing outcomes for some. Support from an oncology team, including help with treatment side effects, fatigue and the stress of an uncertain diagnosis, is an important part of care.
See a doctor about a lump, swollen lymph node or skin lesion that keeps growing or does not go away over a few weeks, especially if it is not tender or keeps enlarging. If you have already been treated for Langerhans cell sarcoma, contact your care team promptly about a new lump, a new skin lesion or new bone pain, since these can signal a return of the disease. During chemotherapy, a fever of 100.5°F (38°C) or higher, chills or other signs of infection need a call to your oncology team right away, because infections during treatment can become serious quickly.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Langerhans Cell Sarcoma is like, what's helped you, or ask the community a question.